camptothecin has been researched along with Acute Lymphoid Leukemia in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (50.00) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 2 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carpenter, G; Chiang, SC; El-Khamisy, S; Kerzendorfer, C; O'Driscoll, M; Outwin, E; Raymond, FL; Schwartz, C; Turner, G; Whibley, A | 1 |
| Holland, JF; Ohnuma, T; Oussenko, IA; Reddy, EP | 1 |
| Cortes, JE; De Jager, RL; Faderl, S; Garcia-Manero, G; Giles, FJ; Jeha, S; Kantarjian, HM; Thomas, DA | 1 |
| Bendele, R; Brown, E; Emerson, DL; Giles, FJ; Gray, A; Hart, K; LeRay, JD; Meyer, D; Pelanne, M; Tomkinson, B | 1 |
| Lee, SH; Sinko, PJ; Su, Y | 1 |
| Masaoka, T; Ohashi, Y; Ohno, R; Okada, K; Ota, K; Shirakawa, S; Taguchi, T | 1 |
| Ariyoshi, Y; Furue, H; Kimura, I; Masaoka, T; Ogawa, M; Oguro, M; Ohno, R; Saito, H; Sakai, Y; Yoshida, Y | 1 |
| Fujimori, A; Hoki, Y; Pommier, Y; Popescu, NC | 1 |
| Ahmed, T; Darzynkiewicz, Z; Feldman, EJ; Halicka, HD; Lake, D; Seiter, K; Traganos, F | 1 |
| Arbuck, S; Beran, M; Bivins, C; Cheson, B; Cortes, J; Estey, E; Giles, F; Kantarjian, H; O'Brien, S; Tran, H; Vey, N | 1 |
| Cortes, J; Estey, E; Garcia-Manero, G; Giles, F; Kantarjian, H; Kornblau, S; Kwari, M; Murgo, A | 1 |
| Andoh, T; Oguro, M; Okada, K; Seki, Y | 1 |
5 trial(s) available for camptothecin and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Salvage Therapy; Stomatitis; Topoisomerase I Inhibitors | 2002 |
[Late phase II clinical study of irinotecan hydrochloride (CPT-11) in the treatment of malignant lymphoma and acute leukemia. The CPT-11 Research Group for Hematological Malignancies].
Topics: Adolescent; Adult; Aged; Anorexia; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Leukemia, Myeloid, Acute; Leukemia, T-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1994 |
[An early phase II study of CPT-11 (irinotecan hydrochloride) in patients with hematological malignancies].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Drug Administration Schedule; Female; Hodgkin Disease; Humans; Irinotecan; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Nausea; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1994 |
Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Colloids; Humans; Leukemia, Myeloid, Acute; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1999 |
Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Camptothecin; Drug Administration Schedule; Hematologic Tests; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sesquiterpenes; Survival Rate | 2001 |
7 other study(ies) available for camptothecin and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
Mutations in Cullin 4B result in a human syndrome associated with increased camptothecin-induced topoisomerase I-dependent DNA breaks.
Topics: Abnormalities, Multiple; Camptothecin; Cell Line; Cullin Proteins; DNA Damage; DNA Topoisomerases, Type I; Humans; Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Syndrome; Ubiquitination | 2010 |
Effect of ON 01910.Na, an anticancer mitotic inhibitor, on cell-cycle progression correlates with RanGAP1 hyperphosphorylation.
Topics: Camptothecin; Cell Cycle; Cell Line, Tumor; DNA Damage; Doxorubicin; Glycine; GTPase-Activating Proteins; Humans; Mitosis; Phosphorylation; Polymerization; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Signal Transduction; Sulfones; SUMO-1 Protein; Tubulin | 2011 |
OSI-211, a novel liposomal topoisomerase I inhibitor, is active in SCID mouse models of human AML and ALL.
Topics: Animals; Antineoplastic Agents; Camptothecin; Disease Models, Animal; Drug Evaluation; Female; Humans; Leukemia, Myeloid, Acute; Mice; Mice, SCID; Neoplasm Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation, Heterologous; Tumor Cells, Cultured | 2003 |
Inhibition of efflux transporter ABCG2/BCRP does not restore mitoxantrone sensitivity in irinotecan-selected human leukemia CPT-K5 cells: evidence for multifactorial multidrug resistance.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Irinotecan; Mitoxantrone; Neoplasm Proteins; Precursor Cell Lymphoblastic Leukemia-Lymphoma; RNA, Small Interfering | 2006 |
Silencing and selective methylation of the normal topoisomerase I gene in camptothecin-resistant CEM/C2 human leukemia cells.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; DNA Methylation; DNA Topoisomerases, Type I; DNA, Neoplasm; Enzyme Induction; Enzyme Inhibitors; Gene Expression Regulation, Leukemic; Humans; In Situ Hybridization, Fluorescence; Neoplasm Proteins; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Tumor Cells, Cultured | 1996 |
Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blast Crisis; Camptothecin; Cytarabine; Drug Administration Schedule; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Topotecan | 1997 |
Collateral drug sensitivity induced in CPT-11 (a novel derivative of camptothecin)-resistant cell lines.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Drug Resistance; Drug Screening Assays, Antitumor; Humans; Irinotecan; Precursor Cell Lymphoblastic Leukemia-Lymphoma; T-Lymphocytes; Topoisomerase II Inhibitors | 1990 |